Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupPlasma cell neoplasmsTransplantationDiseaseMultiple MyelomaStem Cell Transplantation, AutologousSubgroupICD10C90.-C90.0-Z94.80MeSHMultiple MyelomaPlasmacytomaSequenceChemotherapyChemo-substanceMelphalanChemo-substanceMelphalanChemo-substanceMelphalanChemo-substanceMelphalanNo. Substances1 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronNo. Substances6Protocol classificationTherapy classificationcurrent standardIntensityHigh dose myeloablativeTherapy indicationFirst lineTherapy phaseconditioningTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorGoldschmidt HDiseaseMM Stadium II und III, 18-65 Jahre, ECOG 0-3, ErstlinieOriginGerman-Speaking Myeloma Multicenter Group (GMMG), Therapieteil analog der HD-3 StudieProtocols in Revision 1 protocol foundProtocols under revision.High-dose Melphalan 200 before Autologous Stem Cell Transplantation, Multiple Myeloma (PID528 V2.2)
